Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy (CAA) is a neurological condition where amyloid proteins accumulate in the blood vessel walls of the brain, potentially leading to issues like brain hemorrhages and cognitive decline.
Cerebral Amyloid Angiopathy: ALN-APP Treatment Study
We are studying a new treatment called ALN-APP for patients with Cerebral Amyloid Angiopathy. The goal is to see if it helps reduce new brain bleeding and improve overall brain health.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 50 years old?
- Do you have a history of significant cognitive impairment or dementia?
- Are you currently pregnant or breastfeeding?
- Are you taking blood thinners like Warfarin, Clopidogrel, or Apixaban?
- Have you had any major surgery or hospitalization in the last 12 weeks?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Mivelsiran
Aln-961583
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Brain Research Center Amsterdam B.V.
Neurology
Amstelveen, Netherlands
Leids Universitair Medisch Centrum (LUMC)
Neurology
Leiden, Netherlands
Radboud universitair medisch centrum / RADBOUDUMC
Neurology
Nijmegen, Netherlands
Sponsor: Alnylam Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.